Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
The methods of assessing the clinical relevance of a significant difference between antidepressants and placebo are discussed. The commonly used criteria of treatment effect and responder rates, as well as the percentage difference in responders between antidepressant and placebo, are critically reviewed and applied to assess the clinical relevance of the significant advantages reported in double-blind, randomized, controlled studies of escitalopram compared with other antidepressants. A significant advantage for escitalopram has been reported in randomized, double-blind, short-term studies compared with citalopram, paroxetine and duloxetine. The reported significant differences are clinically relevant based on a treatment effect difference of at least 2 points on the Montgomery and Asberg Depression Rating Scale as well as a significant advantage in the protocolled responder or remission analysis. The mean unadjusted treatment effect advantage for escitalopram compared with the antidepressants studied is 2.42 points on the Montgomery and Asberg Depression Rating Scale in the short-term treatment. Excluding one study that did not report short-term responder rates, there were significantly more responders on escitalopram (74%) than comparators (63%). Both of these measures demonstrate a clinically relevant difference in favour of escitalopram.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the observed 24.0 difference exceeded minimum clinically important difference thresholds reported in the literature (26,27).”
In the citing paper
“which is considered a clinically meaningful treatment difference (26,27) suggesting rapid onset of antidepressant efficacy.”
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Self-citationDevelopment of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors
Thase, M. E., Entsuah, A. R., & Rudolph, R. L. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.178.3.234 · Cited by 801
Khan, A., Leventhal, R. M., Khan, S. R., & Brown, W. A. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200202000-00007 · Cited by 456
Kennedy, S. H., Andersen, H. F., & Lam, R. W. (2006) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0615 · Cited by 216
Moore, N., Verdoux, H., & Fantino, B. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200505000-00002 · Cited by 188
Gorman, J. M., Korotzer, A., & Su, G. (2002) · CNS Spectrums · doi:10.1017/s1092852900028595 · Cited by 169
Which antidepressants have demonstrated superior efficacy? A review of the evidence
Montgomery, S. A., Baldwin, D. S., Blier, P., Fineberg, N. A., Kasper, S., Lader, M., Lam, R. W., Lépine, J.-P., Möller, H.-J., Nutt, D. J., et al. (2007) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282eff7e0 · Cited by 165
Self-citationNierenberg, A. A., Greist, J. H., Mallinckrodt, C. H., Prakash, A., Sambunaris, A., Tollefson, G. D., & Wohlreich, M. M. (2007) · Current Medical Research and Opinion · doi:10.1185/030079906x167453 · Cited by 131
Melander, H., Salmonson, T., Abadie, E., & van Zwieten-Boot, B. (2008) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.06.003 · Cited by 117
Boulenger, J.-P., Huusom, A. K. T., Florea, I., Bækdal, T., & Sarchiapone, M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x115513 · Cited by 110
Wade, A., Gembert, K., & Florea, I. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x210732 · Cited by 102
Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis
Kasper, S., Spadone, C., Verpillat, P., & Angst, J. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000194375.42589.c3 · Cited by 100
Khan, A., Bose, A., Alexopoulos, G. S., Gommoll, C., Li, D., & Gandhi, C. C. (2007) · Clinical Drug Investigation · doi:10.2165/00044011-200727070-00005 · Cited by 97
Lepola, U., Wade, A., & Andersen, H. F. (2004) · International Clinical Psychopharmacology · doi:10.1097/00004850-200405000-00005 · Cited by 91
Yevtushenko, V. Y., Belous, A., Yevtushenko, Y. G., Gusinin, S. E., Buzik, O. Z., & Agibalova, T. V. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.11.014 · Cited by 83
Comparison of escitalopram and citalopram efficacy: A meta-analysis
Auquier, P., Robitail, S., Llorca, P.-M., & Rive, B. (2003) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500310003408 · Cited by 76
Llorca, P.-M., Azorin, J.-M., Despiegel, N., & Verpillat, P. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2005.00440.x · Cited by 74
Escitalopram versus venlafaxine XR in the treatment of depression
Montgomery, S. A., & Andersen, H. F. (2006) · International Clinical Psychopharmacology · doi:10.1097/00004850-200609000-00008 · Cited by 59
Self-citationAntidepressants and placebos: Secrets, revelations, and unanswered questions.
Kirsch, I., Scoboria, A., & Moore, T. J. (2002) · Prevention & Treatment · doi:10.1037/1522-3736.5.1.533r · Cited by 33
Lam, R. W. M., Andersen, H. F., & Wade, A. G. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282ffdedc · Cited by 29
Antidepressants and placebos: Secrets, revelations, and unanswered questions.
Kirsch, I., Scoboria, A., & Moore, T. J. (2002) · Prevention & Treatment · doi:10.1037//1522-3736.5.0033r · Cited by 29
Research works printed but not linked: 1
- Kennedy, 2006, J Psychiatry Neurosci, 31, 122
Cited by
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., et al. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19020172 · Cited by 904
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Taken together, results from meta-analyses suggest superiority of intravenous ketamine or esketamine when compared with second-generation antipsychotics (19, 143, 150, 151).”
ResultBauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
“Percentage of patients with response or remission is considered to be a meaningful measure of clinical relevance (Montgomery and Moller 2009).”
BackgroundSelf-citationFedgchin, M., Trivedi, M., Daly, E. J., Melkote, R., Lane, R., Lim, P., Vitagliano, D., Blier, P., Fava, M., Liebowitz, M., et al. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz039 · Cited by 606
Ochs-Ross, R., Daly, E. J., Zhang, Y., Lane, R., Lim, P., Morrison, R. L., Hough, D., Manji, H., Drevets, W. C., Sanacora, G., et al. (2020) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.10.008 · Cited by 481
Metadata
- Authors
- Montgomery, S. A., & Möller, H.-J.
- Affiliations
- University of London (GB)
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Montgomery, Stuart A.
- Venue
- International Clinical Psychopharmacology
- Published
- 2009-05
- Volume
- 24
- Issue
- 3
- Pages
- 111-118
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2051198709
- Cited by
- 121
- References
- 22
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 3 · 2023: 11 · 2022: 4 · 2021: 10 · 2020: 6 · 2019: 7 · 2018: 3 · 2017: 4 · 2016: 6 · 2015: 8 · 2014: 10 · 2013: 15 · 2012: 1
- FWCI
- 5.53
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- escitalopram, antidepressants, clinical relevance, treatment effects, responder rate, remission, citalopram, paroxetine, duloxetine, depression, short-term treatment
- MeSH terms
- Depressive Disorder, Major, Major Depressive Disorder, Depressive Disorder, Humans, Psychiatric Status Rating Scales, Citalopram, Antidepressive Agents, Second-Generation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.